ライフサイエンスコーパス: primary sclerosing cholangitis

1 erformed for potentially recurrent diseases (primary sclerosing cholangitis).

2 distinct from UC that is not associated with primary sclerosing cholangitis.

3 aximum of 38.5% observed among patients with primary sclerosing cholangitis.

4 e antigen haplotypes are not associated with primary sclerosing cholangitis.

5 wide association studies as risk factors for primary sclerosing cholangitis.

6 ne hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis.

7 of pregnancy, primary biliary cirrhosis and primary sclerosing cholangitis.

8 infection does not appear to directly cause primary sclerosing cholangitis.

9 ences have been detected in liver tissues in primary sclerosing cholangitis.

10 of pregnancy, primary biliary cirrhosis, and primary sclerosing cholangitis.

11 the only established long-term treatment for primary sclerosing cholangitis.

12 isease onset or immediately in patients with primary sclerosing cholangitis.

13 asia in patients with ulcerative colitis and primary sclerosing cholangitis.

14 patients with inflammatory bowel disease and primary sclerosing cholangitis.

15 tisfactory medical therapy for patients with primary sclerosing cholangitis.

16 plain the association between nonsmoking and primary sclerosing cholangitis.

17 essive familial intrahepatic cholestasis and primary sclerosing cholangitis.

18 ation of MC mediators may be therapeutic for primary sclerosing cholangitis.

19 o benefit both primary biliary cirrhosis and primary sclerosing cholangitis.

20 he severity of primary biliary cirrhosis and primary sclerosing cholangitis.

21 f gallstones, primary biliary cirrhosis, and primary sclerosing cholangitis.

22 ed cholangitis and the steroid-nonresponsive primary sclerosing cholangitis.

23 (17%), primary biliary cirrhosis (16%), and primary sclerosing cholangitis (13%) with an odds ratio

24 4 controls with autoimmune diseases (18 with primary sclerosing cholangitis, 16 with autoimmune hepat

25 as primary biliary cirrhosis (8.2%; P<0.05), primary sclerosing cholangitis (5.2%; P<0.05) or alcohol

26 ic (4.7% vs. 0.6%), hepatobiliary (including primary sclerosing cholangitis) (5.5% vs. 0.1%), pancrea

27 atitis and primary biliary cirrhosis (7%) or primary sclerosing cholangitis (6%) and autoimmune chola

28 h malignancies (46.4%) and 114 patients with primary sclerosing cholangitis (62.3%).

29 than patients with autoimmune hepatitis and primary sclerosing cholangitis (75% vs. 22%, P = .03) or

30 in the biliary epithelia of 30 patients with primary sclerosing cholangitis (a premalignant disease o

31 n of colitis, extensive colonic involvement, primary sclerosing cholangitis, a family history of colo

32 autoimmune pancreatitis in association with primary sclerosing cholangitis, a syndrome with distinct

33 (e.g., primary biliary cirrhosis [PBC], and primary sclerosing cholangitis) account for approximatel

34 d on BDs in CLDs (primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease,

35 A stratified sample of 184 patients with primary sclerosing cholangitis and age- and sex-matched

36 iation between the autoimmune liver diseases primary sclerosing cholangitis and autoimmune hepatitis

37 Primary biliary cirrhosis, primary sclerosing cholangitis and biliary atresia are t

38 tors, were up-regulated by cholangiocytes in primary sclerosing cholangitis and cholangiocarcinoma.

39 Primary sclerosing cholangitis and immunosuppressive use

40 preneoplastic bile duct inflammatory disease primary sclerosing cholangitis and in human cholangiocar

41 1.3 +/- 1.9, P < .005) and in patients with primary sclerosing cholangitis and in severity were inde

42 n particular, the strong comorbidity between primary sclerosing cholangitis and inflammatory bowel di

43 r-pancreas transplantation in a patient with primary sclerosing cholangitis and insulin-dependent dia

44 of therapies for primary biliary cirrhosis, primary sclerosing cholangitis and intrahepatic cholesta

45 Three subjects were studied: two with primary sclerosing cholangitis and one normal control.

46 th other immune-mediated diseases, including primary sclerosing cholangitis and primary biliary cirrh

47 uclear YAP in the bile ductular reactions of primary sclerosing cholangitis and primary biliary cirrh

48 ing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis to

49 trahepatic cholestasis, biliary atresia, and primary sclerosing cholangitis, and clinical trials of t

50 sis, hepatitis C, primary biliary cirrhosis, primary sclerosing cholangitis, and cryptogenic cirrhosi

51 Patients with autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirr

52 s, recurrent autoimmune hepatitis, recurrent primary sclerosing cholangitis, and recurrent primary bi

53 The relationship between a related disease, primary sclerosing cholangitis, and smoking is unknown.

54 Patients with ulcerative colitis and primary sclerosing cholangitis are at high risk for colo

55 the diagnoses of primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, he

56 ndromes including primary biliary cirrhosis, primary sclerosing cholangitis, biliary atresia, and pro

57 tors for CC, including parasitic infections, primary sclerosing cholangitis, biliary-duct cysts, hepa

58 roid-sensitive biliary strictures resembling primary sclerosing cholangitis but with increased serum

59 re comparable with those in patients without primary sclerosing cholangitis, but there is a higher ra

60 s reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulati

61 C alleles in a large group of patients with primary sclerosing cholangitis by using a recently devel

62 Differentiation of primary sclerosing cholangitis can be challenging becaus

63 nescence may play a role in biliary atresia, primary sclerosing cholangitis, cellular rejection, and

64 duration of ulcerative colitis; duration of primary sclerosing cholangitis; Child-Pugh classificatio

65 and treatment of primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy

66 and treatment of primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy

67 isease (including primary biliary cirrhosis, primary sclerosing cholangitis, chronic hepatitis C, and

68 y brush samples (15 CCAs and 20 nonmalignant primary sclerosing cholangitis controls), and the methyl

69 orming markers was validated (34 CCAs and 34 primary sclerosing cholangitis controls).

70 llular carcinoma, primary biliary cirrhosis, primary sclerosing cholangitis, ethanol, and cryptogenic

71 Other data collected included history of primary sclerosing cholangitis, family history of colore

72 and 109 cholangiograms) of 189 patients with primary sclerosing cholangitis, five of whom were prospe

73 Patients with autoimmune hepatitis and primary sclerosing cholangitis had a higher frequency of

74 The natural history of large and small duct primary sclerosing cholangitis has been reviewed.

75 Patients with primary sclerosing cholangitis have a poor prognosis; pr

76 number of patients previously diagnosed with primary sclerosing cholangitis have autoimmune pancreati

77 morphisms associated with protection against primary sclerosing cholangitis have been elucidated.

78 eucocyte antigen haplotype associations with primary sclerosing cholangitis have been investigated.

79 Multiple gene polymorphisms associated with primary sclerosing cholangitis have been investigated.

80 8.2%, and primary biliary cirrhosis (PBC) or primary sclerosing cholangitis in 35.7%.

81 e enrolled 105 patients with well-documented primary sclerosing cholangitis in a randomized, double-b

82 Primary sclerosing cholangitis in children can mimic aut

83 ost-effective and accurate way of diagnosing primary sclerosing cholangitis in comparison with endosc

84 The estimated odds of having primary sclerosing cholangitis in current smokers compar

85 re is a higher rate of retransplantation for primary sclerosing cholangitis in most centers.

86 and future research efforts should focus on primary sclerosing cholangitis, in addition to primary b

87 Symptoms of primary sclerosing cholangitis include fatigue, jaundice

88 hepatic morphology observed in patients with primary sclerosing cholangitis-induced end-stage cirrhos

89 Primary sclerosing cholangitis-inflammatory bowel diseas

90 diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, intrahepatic cholestasis

91 Primary sclerosing cholangitis is a chronic cholestatic

92 Primary sclerosing cholangitis is a chronic cholestatic

93 Primary sclerosing cholangitis is a chronic cholestatic

94 Primary sclerosing cholangitis is a chronic cholestatic

95 Primary sclerosing cholangitis is a chronic cholestatic

96 Primary sclerosing cholangitis is a chronic cholestatic

97 Primary sclerosing cholangitis is a chronic cholestatic

98 Primary sclerosing cholangitis is a chronic immune-media

99 Primary sclerosing cholangitis is a chronic, progressive

100 Primary sclerosing cholangitis is a progressive inflamma

101 The genetic susceptibility to primary sclerosing cholangitis is associated, in part, w

102 Liver histology in primary sclerosing cholangitis is characterized by a por

103 Treatment of primary sclerosing cholangitis is confined to supportive

104 ns indicate that the colitis associated with primary sclerosing cholangitis is pathophysiologically d

105 Primary sclerosing cholangitis is strongly linked to inf

106 Genetic heterogeneity among patients with primary sclerosing cholangitis is supported, and further

107 Primary sclerosing cholangitis is the classic hepatobili

108 The etiopathogenesis of primary sclerosing cholangitis is unknown.

109 The best-studied drug in primary sclerosing cholangitis is ursodeoxycholic acid,

110 meric limit of HLA-encoded susceptibility to primary sclerosing cholangitis lies close to the HLA C l

111 ucts of PBC livers, compared with normal and primary sclerosing cholangitis livers.

112 It is suggested that primary sclerosing cholangitis may have a bacterial caus

113 Primary sclerosing cholangitis may overlap with autoimmu

114 Primary sclerosing cholangitis mice and patients have in

115 but any model to explain the development of primary sclerosing cholangitis must take into account th

116 Sera from patients with PBC (n = 47), primary sclerosing cholangitis (n = 15), and healthy vol

117 immune pancreatitis (n = 34) from those with primary sclerosing cholangitis (n = 17) and CA (n = 17).

118 mined sera from patients with PBC (n = 105), primary sclerosing cholangitis (n = 70), and rheumatoid

119 Strictures in patients with primary sclerosing cholangitis (n = 86) were analyzed se

120 K for primary biliary cirrhosis (PBC, n=76), primary sclerosing cholangitis (n=81), hepatitis C virus

121 is unresectable or arising in the setting of primary sclerosing cholangitis, neoadjuvant chemoradioth

122 dvances in nonalcoholic fatty liver disease, primary sclerosing cholangitis, neonatal hemochromatosis

123 ecent advancements in the areas of childhood primary sclerosing cholangitis, nonalcoholic fatty liver

124 s, and nine (39%) of 23 patients with either primary sclerosing cholangitis or biliary atresia, compa

125 onor first LT for primary biliary cirrhosis, primary sclerosing cholangitis, or alcoholic cirrhosis (

126 une hepatitis and primary biliary cirrhosis, primary sclerosing cholangitis, or chronic viral hepatit

127 gy (overall P = .003), as well as absence of primary sclerosing cholangitis (P = .011).

128 f hepatitis C virus (P = 0.01, HR = 1.6) and primary sclerosing cholangitis (P = 0.03, HR = 2.9).

129 identified in a univariate analysis included primary sclerosing cholangitis (P=0.009) and symptomatic

130 iver and human liver samples from control or primary sclerosing cholangitis patients were evaluated f

131 IgG4 has been demonstrated in a subgroup of primary sclerosing cholangitis patients, which may indic

132 in large bile ducts from the hilar region of primary sclerosing cholangitis patients.

133 ay improve CCA detection, particularly among primary sclerosing cholangitis patients.

134 Underlying primary sclerosing cholangitis, percutaneous biliary int

135 mains the most studied medical treatment for primary sclerosing cholangitis; pilot studies suggest a

136 senger RNA (mRNA) in PBC liver compared with primary sclerosing cholangitis (PSC) (P <.05) or normal

137 The prevalence of primary sclerosing cholangitis (PSC) among patients with

138 tion for primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) and assessed both v

139 ic fibrosis occurs during the progression of primary sclerosing cholangitis (PSC) and is characterize

140 r (including bile duct epithelium) varies in primary sclerosing cholangitis (PSC) and primary biliary

141 Primary sclerosing cholangitis (PSC) and primary biliary

142 dentified colorectal cancer in patients with primary sclerosing cholangitis (PSC) and ulcerative coli

143 Patients with primary sclerosing cholangitis (PSC) are at an increased

144 Patients with primary sclerosing cholangitis (PSC) are at increased ri

145 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent auto

146 Histologic scoring systems specific for primary sclerosing cholangitis (PSC) are not validated.

147 (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) are scarce.

148 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are uncommon liver

149 nts with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) at 3 transplantatio

150 improves serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improv

151 stasis and hepatic histology compatible with primary sclerosing cholangitis (PSC) but normal findings

152 Clinical decisions in primary sclerosing cholangitis (PSC) depend upon underst

153 s to deceased donor livers for patients with primary sclerosing cholangitis (PSC) due to the weightin

154 Recurrence of primary sclerosing cholangitis (PSC) following liver tra

155 Primary sclerosing cholangitis (PSC) has been suggested

156 Patients with primary sclerosing cholangitis (PSC) have a significantl

157 Approximately 60%-80% of patients with primary sclerosing cholangitis (PSC) have concurrent ulc

158 e cholangiography (MRC) for the diagnosis of primary sclerosing cholangitis (PSC) have described comp

159 tors for developing varices in patients with primary sclerosing cholangitis (PSC) have not been well

160 The epidemiology of primary sclerosing cholangitis (PSC) in the United State

161 Primary sclerosing cholangitis (PSC) is a chronic bile d

162 Primary sclerosing cholangitis (PSC) is a chronic choles

163 Primary sclerosing cholangitis (PSC) is a chronic choles

164 Primary sclerosing cholangitis (PSC) is a chronic choles

165 Primary sclerosing cholangitis (PSC) is a chronic choles

166 Primary sclerosing cholangitis (PSC) is a chronic fibroi

167 Primary sclerosing cholangitis (PSC) is a chronic, fibro

168 Primary sclerosing cholangitis (PSC) is a chronic, idiop

169 Primary sclerosing cholangitis (PSC) is a disease of unk

170 Primary sclerosing cholangitis (PSC) is a rare but impor

171 Primary sclerosing cholangitis (PSC) is a rare progressi

172 Primary sclerosing cholangitis (PSC) is a rare, but seri

173 Primary sclerosing cholangitis (PSC) is a severe liver d

174 Primary sclerosing cholangitis (PSC) is an incurable cho

175 BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an orphan hepato

176 Genetic susceptibility to primary sclerosing cholangitis (PSC) is associated with

177 Primary sclerosing cholangitis (PSC) is increasingly dia

178 m; however, with the exception of Notch-3 in primary sclerosing cholangitis (PSC) livers, expression

179 Patients with primary sclerosing cholangitis (PSC) may be at higher ri

180 Patients with primary sclerosing cholangitis (PSC) may develop and ble

181 Pathogenesis of primary sclerosing cholangitis (PSC) may involve impaire

182 linical features of patients with small-duct primary sclerosing cholangitis (PSC) occurring with and

183 biliary stricture formation in patients with primary sclerosing cholangitis (PSC) or after liver tran

184 expressed specifically in cholangiocytes of primary sclerosing cholangitis (PSC) patients and in mic

185 Primary sclerosing cholangitis (PSC) patients pose a par

186 Primary sclerosing cholangitis (PSC) patients suffer fro

187 Primary sclerosing cholangitis (PSC) predisposes individ

188 To summarize publications on juvenile primary sclerosing cholangitis (PSC) published over the

189 The possibility of primary sclerosing cholangitis (PSC) recurrence after li

190 The pathogenesis of primary sclerosing cholangitis (PSC) remains poorly unde

191 nts with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) seen at the Mayo Cl

192 For patients with primary sclerosing cholangitis (PSC) suffering from bact

193 Primary sclerosing cholangitis (PSC) was present in 31/1

194 ents who underwent liver transplantation for primary sclerosing cholangitis (PSC) were analyzed using

195 ents with primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC) who underwent ortho

196 had a history of either IBD (29 patients) or primary sclerosing cholangitis (PSC) without evidence of

197 er specimens, including 64 with PBC, 19 with primary sclerosing cholangitis (PSC), 6 with non-A, non-

198 Primary sclerosing cholangitis (PSC), a chronic inflamma

199 Primary sclerosing cholangitis (PSC), age, history of ch

200 59 subjects, including 28 with PBC, 13 with primary sclerosing cholangitis (PSC), and 18 healthy con

201 er diseases primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and alcoholic live

202 nt in patients with ulcerative colitis (UC), primary sclerosing cholangitis (PSC), and autoimmune hep

203 Several conditions, such as primary sclerosing cholangitis (PSC), are risk factors.

204 f pancreatic tissue from patients with AP or primary sclerosing cholangitis (PSC), as well as from mi

205 pidemiology and natural history of pediatric primary sclerosing cholangitis (PSC), autoimmune scleros

206 In primary sclerosing cholangitis (PSC), bile fluid is freq

207 of hepatolithiasis and 20 archival cases of primary sclerosing cholangitis (PSC), both of which are

208 ammatory bowel disease may be accompanied by primary sclerosing cholangitis (PSC), but seldom primary

209 e of the 135 control sera from patients with primary sclerosing cholangitis (PSC), chronic autoimmune

210 particularly primary biliary cholangitis and primary sclerosing cholangitis (PSC), evolve over time w

211 Primary sclerosing cholangitis (PSC), first described in

212 formance for detecting cholangiocarcinoma in primary sclerosing cholangitis (PSC), particularly when

213 ncluding primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an im

214 Cholangiocyte senescence has been linked to primary sclerosing cholangitis (PSC).

215 une-mediated inflammatory diseases including primary sclerosing cholangitis (PSC).

216 but has not been well studied in those with primary sclerosing cholangitis (PSC).

217 of ursodeoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC).

218 ncluding primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).

219 itis B, primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).

220 in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC).

221 advanced primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).

222 shown to be ineffective in the treatment of primary sclerosing cholangitis (PSC).

223 ix metalloproteinase 3) on susceptibility to primary sclerosing cholangitis (PSC).

224 atory bowel disease differentiated them from primary sclerosing cholangitis (PSC).

225 end-stage primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC).

226 the assessment of survival in patients with primary sclerosing cholangitis (PSC).

227 patients with end-stage liver disease due to primary sclerosing cholangitis (PSC).

228 lantation in the management of patients with primary sclerosing cholangitis (PSC).

229 orthotopic liver transplantations (OLT) for primary sclerosing cholangitis (PSC).

230 biliary fibrosis in animal models and human primary sclerosing cholangitis (PSC).

231 reflecting disease activity and prognosis in primary sclerosing cholangitis (PSC).

232 ogression of cholangiopathies, in particular primary sclerosing cholangitis (PSC).

233 cell-mediated biliary injury is a feature of primary sclerosing cholangitis (PSC).

234 gallstone, other benign disease, tumour, and primary sclerosing cholangitis (PSC).

235 mended for management of adult patients with primary sclerosing cholangitis (PSC).

236 logic standard of reference for diagnosis of primary sclerosing cholangitis (PSC).

237 BDL) rats; however, no information exists in primary sclerosing cholangitis (PSC).

238 emiology and disease course in patients with primary sclerosing cholangitis (PSC).

239 e only treatment for patients with end-stage primary sclerosing cholangitis (PSC); however, selection

240 ave been reported in 9%-15% of patients with primary sclerosing cholangitis (PSC); it is not clear wh

241 skin malignancy was highest in patients with primary sclerosing cholangitis (PSC; 22% at 10 years) or

242 for primary biliary cirrhosis (PBC; n=3052), primary sclerosing cholangitis (PSC; n=3854), hepatitis

243 mplied greater primary dysfunction GF, while primary sclerosing cholangitis (PSC; P=0.0002) implied g

244 [BA], primary biliary cholangitis [PBC], and primary sclerosing cholangitis [PSC]), we built a compre

245 nd other bacteria in the etiopathogenesis of primary sclerosing cholangitis remains to be determined.

246 Circulating lymphocytes from patients with primary sclerosing cholangitis showed rolling adhesion o

247 ellular carcinoma (HCC) (SMR 38.4-18.8), and primary sclerosing cholangitis (SMR 11.0-4.2), and deter

248 tivariable modeling using RC, FISH, age, and primary sclerosing cholangitis status can be used to est

249 omy FISH, trisomy FISH, suspicious cytology, primary sclerosing cholangitis status, and age were asso

250 d more frequently (P < .05) in patients with primary sclerosing cholangitis than in patients with cir

251 d more frequently (P < .05) in patients with primary sclerosing cholangitis than in the other 472 pat

252 Yet different from patients with primary sclerosing cholangitis, the expression of CCL25

253 orphisms do not confer any susceptibility to primary sclerosing cholangitis; the role of intercellula

254 iver disease, non-alcoholic steatohepatitis, primary sclerosing cholangitis, total parenteral nutriti

255 cently demonstrated in biliary lithiasis and primary sclerosing cholangitis, two cholangiopathies reg

256 ation between inflammatory bowel disease and primary sclerosing cholangitis underscores the need to f

257 In a group of patients with well-defined primary sclerosing cholangitis, ursodiol provided no cli

258 Cirrhosis not related to primary sclerosing cholangitis was associated with both

259 Primary sclerosing cholangitis was associated with intra

260 Primary sclerosing cholangitis was more strongly associa

261 Isolated inflammatory bowel disease without primary sclerosing cholangitis was not associated with a

262 A paucity of research studies on primary sclerosing cholangitis was noted in this review

263 The odds of having primary sclerosing cholangitis was significantly decreas

264 patients with inflammatory bowel disease and primary sclerosing cholangitis was the identification of

265 mary biliary cirrhosis, and 26 patients with primary sclerosing cholangitis were assessed in a unifor

266 For all recipients, female sex and primary sclerosing cholangitis were associated with impr

267 ation of disease, and those with concomitant primary sclerosing cholangitis were at increased risk.

268 patients with end-stage cirrhosis caused by primary sclerosing cholangitis were compared with the fr

269 nce of other inflammatory disorders (such as primary sclerosing cholangitis), whereas it decreases wh

270 59 patients with ulcerative colitis and primary sclerosing cholangitis who were undergoing colon

271 is difficult, particularly in patients with primary sclerosing cholangitis, who are at risk of devel

272 ave associated primary biliary cirrhosis and primary sclerosing cholangitis with genes encoding major

273 brush samples from patients with and without primary sclerosing cholangitis with higher levels of sen